FLT4 and neoplasm: Therefore, we applied Sunitinib as a therapeutic in colorectal cancer, because Sunitinib targets include receptors for platelet-derived growth factor receptors (PDGF-α and PDGF-β receptors) and vascular endothelial growth factor receptors (VEGF-1, VEGF-2 and VEGF-3 receptors) that play a role in both tumor angiogenesis and tumor cell proliferation.